Authors: Ohl ME, Miller DR, Lund BC, Kobayashi T, Miell KR PMID: 34264329 PMCID: PMC8283561 DOI: 10.1001/jamanetworkopen.2021.14741 Abstract Importance: Randomized clinical trials have yielded conflicting results about the effects of remdesivir therapy on survival and length of hospital stay among people with COVID-19. Objective: To examine associations between remdesivir treatment and survival and length of [...]

Authors: Al Sulaiman K, Aljuhani O, Al Dossari M, Alshahrani A, Alharbi A PMID: 34193235 PMCID: PMC8242279 DOI: 10.1186/s13054-021-03648-9 Abstract Background: Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine [...]

Authors: Assimakopoulos SF, Aretha D, Kominos D, Dimitropoulou D, Lagadinou M PMID: 34182881 DOI: 10.1080/23744235.2021.1945675 Abstract Background: N-acetyl-cysteine (NAC) has been previously shown to exert beneficial effects in diverse respiratory diseases, through antioxidant and anti-inflammatory actions. Our aim was to evaluate NAC potential impact in hospitalised patients with COVID-19 pneumonia, in [...]

Authors: Patterson BK, Guevara-Coto J, Yogendra R, Francisco E, Long E, Pise A PMID: 34262570 PMCID: PMC8273732 DOI: 10.3389/fimmu.2021.700782 Abstract Expression of CCR5 and its cognate ligands have been implicated in COVID-19 pathogenesis, consequently therapeutics directed against CCR5 are being investigated. Here, we explored the role of CCR5 and its ligands [...]

Authors: Blum VF, Cimerman S, Huneter JR, Tierno P, Lacerda A, Soeiro A PMID: 34222847 PMCID: PMC8235996 DOI: 10.1016/j.eclinm.2021.100981 Abstract Background: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates' drugs. Nitazoxanide (NTZ) has a broad antiviral effect. Methods: This was a randomized, double-blind pilot clinical trial comparing NTZ 600 [...]

To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences.

Authors:Farnoosh G, Akbaariqomix M, Badri T, Bagheri M, Izadi M. PMID: PMC8220995 DOI: 10.1016/j.arcmed.2021.06.006 Abstract Background: Melatonin has been known as an anti-inflammatory agent and immune modulator that may address progressive pathophysiology of coronavirus disease 2019 (COVID-19). Aim of the study: To evaluate the clinical efficacy of adjuvant, use of melatonin [...]

Authors: Cadegiani FA, McCoy J, Zimerman A, Mirza FN, Barros RN doi: https://doi.org/10.1101/2021.06.22.21259318 Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is mediated by the androgen-promoted protease, transmembrane protease, serine 2 (TMPRSS2). Previously, we have shown that treatment with proxalutamide, a non-steroidal androgen receptor antagonist, accelerates viral clearance and [...]

Authors: Bryant A, Lawrie TA, Dowswell T, Fordham E, Mitchell S, Hill SR et al. PMID: 34145166 PMCID: PMC8248252 DOI: 10.1097/MJT.0000000000001402 Abstract Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed the [...]

Authors: Duarte M, Pelorosso F, Nicolosi L, Salgado V, Vetulli H PMID: 34189447 PMCID: PMC8225700 DOI: 10.1016/j.eclinm.2021.100962 Abstract Background: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 allocation ratio. Participants included patients from 18 [...]